Disruptions in Availability of Breast Biopsy Needles - Letter to Health Care Providers

https://www.fda.gov/medical-devices/letters-health-care-providers/disruptions-availability-breast-biopsy-needles-letter-health-care-providers?utm_medium=email&utm_source=govdelivery Disruptions in Availability of Stereotactic Breast Biopsy Needles - Letter to Health Care Providers Today, the U.S. Food and Drug Administration (FDA) issued a Letter to Health Care Providers to notify providers that we are aware that the United States is experiencing interruptions in the supply of Stereotactic Breast Biopsy Needles because of recent supplier issues. The FDA also updated the expected shortage duration for Stereotactic Breast Biopsy Needles on the medical device shortage list (product code KNW). The disruption in availability of this device is expected to impact patient care and may require adjustments to the clinical management of patients indicated to undergo a breast biopsy. The FDA recommends health care providers consider strategies to conserve the use of Stereotactic Breast Biopsy Needles when possible.